Clinical research of prophylactic hepatic artery infusion chemotherapy af-ter curative resection in patients with pancreatic cancer
- VernacularTitle:胰腺癌术后预防性肝动脉灌注化疗的临床研究
- Author:
Liqin YAO
1
;
Chengwu TANG
;
Wenming FENG
;
Ying BAO
;
Yinyuan ZHENG
Author Information
1. 湖州师范学院附属第一人民医院普通外科
- Keywords:
Pancreatic cancer;
Hepatic artery infusion chemotherapy;
Intrahepatic recurrence;
Metastases
- From:
China Modern Doctor
2015;(3):77-79,83
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of prophylactic hepatic artery infusion chemotherapy (HAIC) on survival after curative resection in patients with primary pancreatic cancer. Methods A total of 106 patients with pancreatic cancer after pancreatectomy received 2 cycles of HAIC plus 4 cycles of systemic chemotherapy (HAIC) or 6 cycles of sys-temic chemotherapy alone (Control). Both the HAIC and systemic chemotherapy regimen consisted of 5-fluorouracil 1000 mg/m2 on day 1 and Gemcitabine 800 mg/m2 on day 1 and 8. The treatment was started on an average of 3 weeks after surgery and repeated every 4 weeks. The disease-free survival , overall survival and liver metastases-free survival were compared. Results Significant differences were found in 3-year overall survival (HAIC, 23.08 %; Control, 14.81%;P=0.0473) and liver metastases-free survival (HAIC, 80.77%;Control, 55.56%;P=0.0014). There was no significant difference in adverse effects between two groups. Conclusion HAIC effectively and safely prevented liver metastases and improved the prognosis of patients with pancreatic cancer after pancreatectomy.
